A Phase IIa, Multi-Centre, Randomised, Double-Blind, Comparator Controlled, Repeated-Dose Study of 2 Dose Levels of AK106 001616 in Patients with Rheumatoid Arthritis.
Phase of Trial: Phase II
Latest Information Update: 27 Jul 2016
At a glance
- Drugs AK 106-001616 (Primary) ; Methotrexate; Naproxen
- Indications Musculoskeletal pain; Rheumatoid arthritis
- Focus Biomarker; Therapeutic Use
- 15 Jun 2013 Results presented at the 14th Annual Congress of the European League Against Rheumatism.
- 06 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 21 Apr 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History